These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18836086)

  • 1. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
    Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M
    Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B; Schulz M; Franke I; Gollnick H
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients].
    Gellrich S; Muche JM; Pelzer K; Audring H; Sterry W
    Hautarzt; 2001 Mar; 52(3):205-10. PubMed ID: 11284065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
    Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
    J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
    Kennedy GA; Blum R; McCormack C; Prince HM
    Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
    Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
    Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature.
    Gitelson E; Al-Saleem T; Millenson M; Lessin S; Smith MR
    Leuk Lymphoma; 2006 Sep; 47(9):1902-7. PubMed ID: 17065004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma.
    Porkert S; Mai P; Jonak C; Weihsengruber F; Rappersberger K; Bauer W; Simonitsch-Klupp I; Raderer M; Valencak J
    Acta Derm Venereol; 2021 Feb; 101(2):adv00383. PubMed ID: 33475146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
    Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
    Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.
    Brandenburg A; Humme D; Terhorst D; Gellrich S; Sterry W; Beyer M
    Br J Dermatol; 2013 Nov; 169(5):1126-32. PubMed ID: 23796422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
    Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
    J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
    Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
    Kalpadakis C; Pangalis GA; Dimopoulou MN; Vassilakopoulos TP; Kyrtsonis MC; Korkolopoulou P; Kontopidou FN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Tsaftaridis P; Plata E; Angelopoulou MK
    Hematol Oncol; 2007 Sep; 25(3):127-31. PubMed ID: 17514771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
    Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
    Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.
    Bishton MJ; Leahy MF; Hicks RJ; Turner JH; McQuillan AD; Seymour JF
    Ann Oncol; 2008 Sep; 19(9):1629-33. PubMed ID: 18522934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
    Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S
    Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.